UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 291

Sortiert nach

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Annals of oncology, 2017-06, Vol.28 (6), p.1368-1379

2017

Volltextzugriff (PDF)

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Annals of oncology, 2019-12, Vol.30 (12), p.2012-2012

2019

Volltextzugriff (PDF)

Circulating innate immune markers and outcomes in treatment-naïve advanced non–small cell lung cancer patients

European journal of cancer (1990), 2019-02, Vol.108, p.88-96

2019

Volltextzugriff (PDF)

Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition

Gene therapy, 2008-11, Vol.15 (21), p.1411-1423

2008

Volltextzugriff (PDF)

Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO)

Annals of oncology, 2018-10, Vol.29, p.viii511-viii511

2018

Volltextzugriff (PDF)

Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)

Annals of oncology, 2019-04, Vol.30, p.ii7-ii8

2019

Volltextzugriff (PDF)

152 Clinical risk factors associated with malignancy in TIF1-γ(+) dermatomyositis

Journal of investigative dermatology, 2024-08, Vol.144 (8), p.S27-S27

2024

Volltextzugriff (PDF)

Measles virus nucleoprotein induces cell-proliferation arrest and apoptosis through NTAIL-NR and NCORE-FcγRIIB1 interactions, respectively

Journal of general virology, 2005-06, Vol.86 (6), p.1771-1784

2005

Volltextzugriff (PDF)

Calcinose pseudo-tumorale du poignet au cours d'une sclérodermie

La Presse médicale (1983), 1999-06, Vol.28 (22)

1999

Volltextzugriff (PDF)

Ostéoarthropathie hypertrophiante secondaire à une tumeur du pancréas

La Presse médicale (1983), 2001-05, Vol.30 (18)

2001

Volltextzugriff (PDF)

11P Senescent immune phenotype (SIP) status that predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients is not associated with chronic type I IFN signature

Annals of oncology, 2021-12, Vol.32, p.S1379

2021

Volltextzugriff (PDF)

1286P Senescent immune phenotype (SIP) status predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients

Annals of oncology, 2021-09, Vol.32, p.S999-S999

2021

Volltextzugriff (PDF)

Dermatomyositis: Practical Guidance and Unmet Needs

ImmunoTargets and therapy, 2024-01, Vol.13, p.151-172

2024

Volltextzugriff (PDF)

1661MO Genomic somatic copy number alterations drive adaptive tumor immune suppression and primary resistance to anti-PD1 + anti-angiogenics in pleural mesothelioma

Annals of oncology, 2022-09, Vol.33, p.S1302-S1303

2022

Volltextzugriff (PDF)

984P Phase I dose escalation trial of nintedanib in combination with pembrolizumab in patients with advanced solid tumors (PEMBIB trial)

Annals of oncology, 2021-09, Vol.32, p.S842-S843

2021

Volltextzugriff (PDF)

PO-1227: A dose escalation phase 1 study of radiotherapy combined with ipilimumab in metastatic melanoma

Radiotherapy and oncology, 2020-11, Vol.152, p.S646-S647

2020

Volltextzugriff (PDF)

1732MO Pembrolizumab and nintedanib for patients with advanced mesothelioma

Annals of oncology, 2021-09, Vol.32, p.S1198-S1198

2021

Volltextzugriff (PDF)

23P Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma

Immuno-oncology technology, 2023-12, Vol.20, p.100492, Article 100492

2023

Volltextzugriff (PDF)

MA07.01 Circulating Immature Neutrophils, Tumor-Associated Neutrophils and dNLR for Identification of Fast Progressors to Immunotherapy in NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S272-S273

2019

Volltextzugriff (PDF)

Identification and characterisation of a group of cervical carcinoma patients with profound downregulation of intratumoral Type 1 (IFNγ) and Type 2 (IL-4) cytokine mRNA expression

European journal of cancer (1990), 2003-03, Vol.39 (5), p.595-603

2003

Volltextzugriff (PDF)

1368P - Ancillary evaluation of systemic immune antitumour response (SIAR) and tumour growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase I study Mel-Ipi-Rx

Annals of oncology, 2019-10, Vol.30, p.v558-v559

2019

Volltextzugriff (PDF)

Ancillary evaluation of systemic immune antitumour response (SIAR) and tumour growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase I study Mel-Ipi-Rx

Annals of oncology, 2019-10, Vol.30, p.v558-v559

2019

Volltextzugriff (PDF)

P1.01-18 Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S466-S467

2018

Volltextzugriff (PDF)

Saint Yves et les Bretons

Jean-Christophe Cassard, Georges Provost (dir.)

2004

Volltextzugriff (PDF)

P1.04-31 Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S452-S452

2019

Volltextzugriff (PDF)

1 – 25 von 291

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(173)
Mit Volltextzugriff
(255)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Circulating innate immune markers and outcomes in treatment-naïve advanced non–small cell lung cancer patients

Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition

Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO)

Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts)

152 Clinical risk factors associated with malignancy in TIF1-γ(+) dermatomyositis

Measles virus nucleoprotein induces cell-proliferation arrest and apoptosis through NTAIL-NR and NCORE-FcγRIIB1 interactions, respectively

Calcinose pseudo-tumorale du poignet au cours d'une sclérodermie

Ostéoarthropathie hypertrophiante secondaire à une tumeur du pancréas

11P Senescent immune phenotype (SIP) status that predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients is not associated with chronic type I IFN signature

1286P Senescent immune phenotype (SIP) status predicts resistance to immune checkpoint blockers (ICB) among CMV+ advanced non-small cell lung cancer (aNSCLC) patients

Dermatomyositis: Practical Guidance and Unmet Needs

1661MO Genomic somatic copy number alterations drive adaptive tumor immune suppression and primary resistance to anti-PD1 + anti-angiogenics in pleural mesothelioma

984P Phase I dose escalation trial of nintedanib in combination with pembrolizumab in patients with advanced solid tumors (PEMBIB trial)

PO-1227: A dose escalation phase 1 study of radiotherapy combined with ipilimumab in metastatic melanoma

1732MO Pembrolizumab and nintedanib for patients with advanced mesothelioma

23P Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma

MA07.01 Circulating Immature Neutrophils, Tumor-Associated Neutrophils and dNLR for Identification of Fast Progressors to Immunotherapy in NSCLC

Identification and characterisation of a group of cervical carcinoma patients with profound downregulation of intratumoral Type 1 (IFNγ) and Type 2 (IL-4) cytokine mRNA expression

1368P - Ancillary evaluation of systemic immune antitumour response (SIAR) and tumour growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase I study Mel-Ipi-Rx

Ancillary evaluation of systemic immune antitumour response (SIAR) and tumour growth rate (TGR) of patients (pts) with metastatic melanoma (MM) treated with radiotherapy (RT) combined with ipilimumab (ipi) in the phase I study Mel-Ipi-Rx

P1.01-18 Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients

Saint Yves et les Bretons

P1.04-31 Immunosenescence Correlates with Poor Outcome from PD-(L)1 Blockade but Not Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)

Suchergebnisse filtern